Peter Radovich Sells 3,177 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 3,177 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $47.92, for a total transaction of $152,241.84. Following the completion of the transaction, the chief operating officer now directly owns 29,588 shares in the company, valued at $1,417,856.96. The trade was a 9.70 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Peter Radovich also recently made the following trade(s):

• On Tuesday, January 7th, Peter Radovich sold 1,998 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $42.82, for a total transaction of $85,554.36.

Mirum Pharmaceuticals Trading Up 0.1 %

Shares of MIRM opened at $48.54 on Wednesday. The stock has a market capitalization of $2.33 billion, a P/E ratio of -24.03 and a beta of 0.98. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.33. The firm has a fifty day simple moving average of $43.90 and a two-hundred day simple moving average of $41.68. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $49.58.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million during the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same period last year, the company posted ($0.57) EPS. On average, research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.45 EPS for the current year.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Mirum Pharmaceuticals by 22.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares in the last quarter. Amalgamated Bank boosted its stake in shares of Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after purchasing an additional 513 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Mirum Pharmaceuticals by 10.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after purchasing an additional 1,003 shares in the last quarter. R Squared Ltd bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $69,000. Finally, Secure Asset Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 9.3% during the 4th quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock valued at $1,651,000 after purchasing an additional 3,406 shares in the last quarter.

Wall Street Analyst Weigh In

Several research firms recently commented on MIRM. HC Wainwright reaffirmed a “buy” rating and set a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners increased their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Citigroup increased their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.